Dr. Yang obtained his Ph.D. in France. He was a visiting scholar at Umass and Mont Sinai Medical Center, USA. He is a research fellow and CEO in Academia Sinica, Taiwan. Dr. Yang’s research aims to promote human and animal health. His expertise covers diabetes, cancer, and drug discovery. He has published ca. 100 high impact papers in the SCI journals. He also serves or served as editors, guest editor in chief, and reviewer in tens journals. Besides, he obtained 43 patents and 9 licensing totalling USD 10 million. As a result, anti-diabetic nutraceuticals and phytogenic formulations for animal health were marketed locally and internationally. Since a paradigm shift of diabetes therapy from glycemic control to β-cell preservation has been prevailing, preservation of β-cell number and function hold the key to treating and curing diabetes. Dr Yang pioneered to study function and mechanism of Pdia4, a master gene that controls β-cell pathogenesis and, in turn, diabetes. Furthermore, PS1, a Pdia4-based drug candidate, was developed using a molecular docking strategy. In 2021, Dr. Yang established a drug development company, Pharmasaga, aiming to move PS1 towards clinical trials. Now, PS1 is on phase 1 clinical trial in humans.